Latest news with #AdemiFirm
Business Wire
3 days ago
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether Flowserve Corporation Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Flowserve (NYSE: FLS) for possible breaches of fiduciary duty and other violations of law in its transaction with Chart Industries. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the reverse merger transaction, shareholders of Flowserve shareholders will own approximately 46.5% of the combined company. Flowserve insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Flowserve by imposing a significant penalty if Flowserve accepts a competing bid. We are investigating the conduct of the Flowserve board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Business Wire
5 days ago
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether Blueprint Medicines Corporation Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Blueprint will receive $129.00 per share, representing an equity value of approximately $9.1 billion. Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. Blueprint insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Blueprint by imposing a significant penalty if Blueprint accepts a competing bid. We are investigating the conduct of the Blueprint board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Business Wire
27-05-2025
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether E2open Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating E2open (NYSE: ETWO) for possible breaches of fiduciary duty and other violations of law in its transaction with WiseTech. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of E2open will receive $3.30 per share in cash equating to an enterprise value of $2.1 billion. E2open public minority shareholders have no voting rights in the transaction and E2open insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for E2open by imposing a significant penalty if E2open accepts a competing bid. We are investigating the conduct of the E2open board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Business Wire
22-05-2025
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether Vigil Neuroscience Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Vigil (Nasdaq: VIGL) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Vigil will receive $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis. Vigil insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Vigil by imposing a significant penalty if Vigil accepts a competing bid. We are investigating the conduct of the Vigil board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Associated Press
22-05-2025
- Business
- Associated Press
Shareholder Alert: The Ademi Firm Investigates Whether Vigil Neuroscience Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--May 22, 2025-- The Ademi Firm is investigating Vigil (Nasdaq: VIGL) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi . Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Vigil will receive $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis. Vigil insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Vigil by imposing a significant penalty if Vigil accepts a competing bid. We are investigating the conduct of the Vigil board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. View source version on CONTACT: Ademi & Fruchter LLP Guri Ademi Toll Free: (866) 264-3995 Fax: (414) 482-8001 KEYWORD: UNITED STATES NORTH AMERICA WISCONSIN INDUSTRY KEYWORD: PROFESSIONAL SERVICES CLASS ACTION LAWSUIT SOURCE: Ademi & Fruchter LLP Copyright Business Wire 2025. PUB: 05/22/2025 08:14 AM/DISC: 05/22/2025 08:13 AM
